Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic, Inc. (Nasdaq: HOLX) generates a steady flow of news centered on women’s health, medical technology innovation and corporate developments. As a company that describes itself as focused on developing technologies to detect, diagnose and treat health conditions, many of its announcements highlight advances in diagnostics, breast imaging, oncology testing and digital pathology.
Investors and healthcare professionals following HOLX news will find updates on Hologic’s diagnostic platforms, such as the Panther and Panther Fusion systems, including regulatory milestones like FDA clearance and CE marking for new assays. Recent communications have covered automated molecular tests for gastrointestinal bacterial pathogens, which expand the company’s infectious disease testing menu and illustrate its emphasis on rapid, molecular-based diagnostics.
Hologic’s news feed also features developments in breast health technologies. The company has publicized data on its AI-powered mammography tools, such as the Genius AI Detection solution and 3DQuorum imaging technology, through studies conducted at major medical centers and presented in peer-reviewed journals or at scientific meetings. These stories often focus on how artificial intelligence can support radiologists by flagging suspicious areas on mammograms and streamlining image review without compromising cancer detection performance.
Oncology and precision medicine are recurring themes. Hologic and its subsidiary Biotheranostics, Inc. issue updates about the Breast Cancer Index Test, including new clinical evidence presented at conferences like the San Antonio Breast Cancer Symposium. These releases describe how the test may inform extended endocrine therapy decisions for patients with early-stage, hormone receptor–positive breast cancer and examine its performance in various patient subgroups.
Beyond technology and clinical data, Hologic’s news includes educational initiatives and partnerships, such as the "Ultimate Defense" cervical cancer screening awareness campaign with professional basketball player Erica Wheeler, and collaborations in epigenomics and pharmaco-epigenetics through Hologic Diagenode and co-marketing agreements. Corporate and financial announcements, including quarterly earnings releases and the proposed acquisition of Hologic by funds managed by Blackstone and TPG, provide additional context for HOLX stockholders.
For readers interested in HOLX news, this page offers a centralized view of Hologic’s product milestones, clinical research, public health campaigns and transaction-related updates, making it a useful resource for tracking how the company’s activities evolve over time.
Hologic Inc. rang the Nasdaq opening bell to commence Breast Cancer Awareness Month, marking the 16th occasion for this event. The company emphasized the importance of regular screenings, highlighting that over 2 billion women worldwide did not undergo cancer screenings in the past year. Tennis legend Martina Navratilova, a breast cancer survivor, joined Hologic's leadership to stress preventive care. The ongoing partnership with the Women’s Tennis Association aims to promote women's health awareness during tournaments and special events.
The second annual Hologic Global Women’s Health Index reveals that over 1.5 billion women lack necessary health screenings, including cancer and diabetes. The report highlights significant barriers to women's health, including food insecurity, safety threats, and educational gaps. The average global health score was just 53 out of 100, with Taiwan leading at 70 and Afghanistan at the lowest with 22. The Index stresses the need for better preventive care, addressing emotional health, and enhancing socioeconomic equity to improve women’s wellbeing.
Hologic, Inc. (NASDAQ: HOLX) announced its participation in two upcoming investor conferences. The first is Wells Fargo’s Healthcare Conference on September 7 at 9:45 a.m. ET, followed by Morgan Stanley’s 20th Annual Global Healthcare Conference on September 13 at 12:20 p.m. ET. Both presentations will be webcast live and available for 30 days post-event through Hologic's investor website. Hologic is dedicated to enhancing women’s health through early detection and treatment.
Hologic, Inc. (NASDAQ: HOLX), a leader in women’s health, announces its sponsorship of Mary J. Blige’s “Good Morning Gorgeous” tour from September 17 to October 29, 2022. The initiative aims to promote preventive care and Well Woman Exams. The partnership includes a sweepstakes for fans to win concert tickets and a public service announcement featuring Blige. Hologic emphasizes the importance of screenings, particularly for underserved communities, showcasing its commitment to women's health.
Hologic, Inc. (NASDAQ: HOLX) received a favorable ruling from the U.S. Court of Appeals for the Federal Circuit, which upheld a 2018 district court decision blocking Minerva from disputing the validity of patents assigned to Hologic. This ruling, relating to a lawsuit filed in 2015 over alleged patent infringement by Minerva’s endometrial ablation system, requires Minerva to pay Hologic over $7 million in damages. Hologic's acquisition of Novacept's patents in 2004 has been confirmed, fostering confidence for companies acquiring innovative technologies in the medical field.
Active Motif has licensed its foundational patents in transposition for CUT&Tag epigenetic assays to Diagenode S.A., a Hologic company (NASDAQ: HOLX). This licensing agreement aims to enhance the understanding of biological processes through improved access to patented technologies, including US9938524 and others. The Cut&Tag-IT technology will aid mechanistic, translational, and clinical research. Active Motif focuses on developing tools for nuclear function analysis, serving a global customer base in scientific and pharmaceutical fields.
Hologic, Inc. reported third-quarter revenue of $1.003 billion, with GAAP diluted EPS of $0.90 and non-GAAP diluted EPS of $0.95, exceeding expectations. Global organic molecular diagnostics revenue grew over 20% in constant currency, while overall revenue declined 14.2% year-over-year, mainly due to lower COVID-19 assay sales and semiconductor supply chain issues. The company has raised its full-year revenue and EPS guidance, reflecting confidence in its diagnostics and surgical business.
Hologic, Inc. (NASDAQ: HOLX) is set to showcase its innovative breast and skeletal health solutions at the European Congress of Radiology in Vienna from July 13-17. The company aims to address challenges in early detection caused by pandemic delays. Attendees can explore Hologic's 3D Mammography™ technology and participate in scientific talks at the Scientific Innovation Hub. Highlights from the inaugural Hologic Global Women’s Health Index will also be shared, focusing on women's health perspectives. This event underscores Hologic's commitment to improving women's health.
Hologic, Inc. (Nasdaq: HOLX) has launched its Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and Novodiag® RESP-4 assay in the European Union, enhancing its molecular diagnostics offerings for the upcoming respiratory viral season. These assays identify four prevalent respiratory viruses, using nasopharyngeal swab samples. The products comply with EU regulations and aim to improve patient care by allowing healthcare providers to differentiate between similar viral infections. This marks a significant expansion in Hologic's diagnostic capabilities following the acquisition of Mobidiag.
Hologic, Inc. (NASDAQ: HOLX) will release its third quarter fiscal 2022 financial results on July 27, after market close. A conference call is scheduled for 4:30 p.m. ET that day. Interested parties can join by calling 800-289-0720 in the U.S. or +1-323-701-0160 internationally, using access code 6025981. The call will also be available via a live webcast on the company's investor website, and an archived replay will be provided after the call for 30 days.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
